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INTRODUCTION
The number of patients with type 2 diabetes mellitus
world-wide has increased rapidly. The growing incidence
of type 2 diabetes is due to life-style factors, i. e. increased
caloric intake and decreased physical activity. Diabetes
mellitus is considered to be mainly the result of an
inadequate supply of insulin, i.e. decreased insulin
secretion and insulin resistance. Sulfonylurea (SU)
derivatives which stimulates insulin secretion from
β-cells of pancreas are widely used in the treatment
of diabetes. Major complications associated with SU
agents are hypoglycemia, weight gain and the ex-
haustion of beta (β) cells with its hyper-insulinemic
effect.
Insulin resistance ultimately involves the development
of obesity, metabolic disorder, hypertension and
atherosclerotic diseases. Therefore, concepts such as
“syndrome X”,“deadly quartet”,“visceral fat syndrome”,
“multiple risk factor syndrome”and“metabolic syndrome”
are used to describe this situation, and comprehensive
therapy that addresses these clinical conditions is
required. Recent drug strategies are also targeted
to improve insulin resistance rather than the promotion
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of insulin secretion.
Although glimepiride, a third-generation SU agent,
has lesser insulin secretion action from the pancreatic
β-cells compared with the conventional SU agent,
its hypoglycemic action is equivalent to conventional
SU agents (1). It has recently been reported that plasma
adiponectin levels increase after the administration of
glimepiride (2). Adiponectin shows anti-atherosclerotic
effects on the vascular wall, and insulin sensitivity
is increased in skeletal muscle and liver. The unique
effects of this drug might be useful in patients with
metabolic syndrome.
In the present study, plasma adiponectin, high
sensitive-CRP (hs-CRP), tumor necrosis factor -α
(TNF-α), interleukin-6 (IL-6), homeostasis model
assessment-insulin resistance (HOMA-IR), brachial-
ankle pulse wave velocity (baPWV) and augmentation
index (AI) were measured before and 28 weeks after
the administration of glimepiride, and the effects of
this diabetic drug on insulin resistance, inflammatory
cytokines and anti-atherosclerotic effect were examined.
PATIENTS AND METHODS
1) Patients
Forty-six patients with type 2 diabetes mellitus
(30 men and 16 women) participated in the present
study. Patients who had coronary artery disease or
arteriosclerosis obliterans were excluded from the
study. Written informed consent was obtained from
all subjects before their participation. Of 34 patients
who were given glibenclamide, they were randomly
divided into two groups. The medication for twenty
patients (13 men and 7 women) was changed to
glimepiride with their consent (GP group), and the
other 14 patients (9 men and 5 women) underwent a
continuous administration of glibenclamide (GB group).
Twelve patients (8 men and 4 women) who were
undergoing insulin therapy (INS group) were enrolled
for comparison in the present study.
The patient characteristics of the present study are
shown on Table 1. There were no significant dif-
ferences in age, systolic blood pressure, body mass
index (BMI), fasting plasma glucose, glycohemo-
globin (HbA1c), HOMA-IR between the GB and
GP groups at the start of the study. The INS groupwas
younger in comparison with the GB and GP groups
(p<0.01), and fasting plasma glucose and HbA1c
levels were significantly higher in INS group (p<0.01).
2) Change from glibenclamide to glimepiride
According to a previous report by Inukai (3),
glibenclamide is converted to glimepiride at a dose
of glimepiride 1mg for glibenclamide 1.25mg in the
GP group. Therefore, referring to plasma glucose levels,
the glimepiride dosage was progressively decreased
or increased up to maximal dose of 6 mg/day. Pulse
wave velocity, BMI and biochemical examinations
were conducted before and 28 weeks after the ad-
ministration of glimepiride
3) Pulse wave velocity, BMI and biochemical
examinations
Blood pressure, pulse wave velocity andBMI were
measured, and biochemical examinations, including
fasting plasma glucose (FPG), immunoreactive insulin
(IRI), adiponectin, hs-CRP, TNF-α, IL-6 was carried
out during the continuous therapy (GB and INS groups)
before and 28 weeks after therapy (GP group).
After a 15-minute bed rest in a supine position,
baPWV was measured using a sphygmomanometer
and a sphygmograph device (FORM PWV/ABI,
COLINMedical Technology Co. Ltd., Tokyo, Japan).
In addition to recording the limb lead ECG and
phonocardiograms, mechanocardiograms were si-
multaneously recorded by attaching blood pressure
cuffs with a tonometic sensor to the bilateral upper
arms and ankles to measure the pulse transit time
(PTT) of arterial waves from the right brachial artery
to the ankle artery. Using these data, baPWV was
obtained by dividing the length of blood vessels
between the heart and inferior limb (L, which was
obtained from the height using a regression formula)
by PTT : baPWV=L / PTT (cm/sec)(4). In the present
study, a higher value of baPWV, which was obtained
at the bilateral arteries in the inferior limbs, was
employed. Although values in which significant noise
occurred were recalculated, the recording was
successfully performed for all subjects.
The augmentation index (AI) was obtained by
Table 1. Patient profiles at baseline
Group GB GP INS
n(case)
gender(M/F)
Age(year)
SBP(mmHg)
BMI(kg/m２)
FPG(mg/dl)
HbA1c(%)
HOMA-IR
14
9/5
71.7±6.2
152±22
24.2±2.2
146±38
7.8±2.0
2.33±2.6
20
13/7
70.2±7.6
148±26
22.3±3.6
152±22
7.7±1.9
2.41±2.9
12
8/4
65.6±8.2＊
156±24
23.4±6.2
159±42＊
8.6±2.2＊
―
＊ p<0.01 vs GB and GP group
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detecting carotid arterial waveforms using a carotid
arterial sensor (CAP-350, COLINMedical Technology
Co. Ltd., Tokyo, Japan) and a multi-tonometric sensor.
The systolic arterial waveforms consist of two different
waves (percussion waves and tidal waves), and
O’Rourke et al .(5) reported that the ratio of the
differences in height between the tidal waves and
percussion waves to the height of all waves was AI,
an index of arteriosclerosis. AI may facilitate the
evaluation of the severity of arterial wall sclerosis
caused by endothelial cell dysfunction during the
initial stage of arteriosclerosis (6).
BMI was obtained using the following equation.
BMI=(body weight; kg)/(height;m)2. As an index
of insulin resistance, HOMA-IR was obtained using
the following equation. HOMA-IR = FPG(mg/dl)×
fasting IRI(mU/ml)÷405
An enzyme immunoassay(BML Co. Ltd., Tokyo,
Japan) was used to determine adiponectin, hs-CRP,
TNF-α and IL-6.
4) Statistical analysis.
All values were expressed as the mean ± SD.
Statistical analyses were performed using the Student’s
paired t -test (two-tail), and values of p<0.05 were
considered to indicate statistical significance. The chi
square test was used to examine differences with
categorical variables. Data analysis was performed
using the StatView statistical software (Stat View 5.0;
SAS Institute, Inc., Cary, NC, USA).
RESULTS
1) Blood pressure, BMI, FPG, HbA1c and HOMA-IR
among GB, GP and INS groups.
Table 2 shows data for blood pressure, BMI, FPG,
HbA1c and HOMA-R for the GB, GP and INS groups
28 weeks after the start of the study. No significant
differences in blood pressure and BMI were found
among the groups. In a comparison of the GB group
and INS group, FPG was significantly lower in the
GP group (p<0.01). HbA1c and HOMA-IR in the GP
group were significantly lower compared to GB
group (p<0.01).
2) PWV before and 28 weeks after glimepiride ad-
ministration
Figure 1 shows a representative case of baPWV,
AI, adiponectin, TNF-α, IL-6 and hs-CRP before and
28 weeks after glimepiride administration (73 year
old male). The baPWVwas decreased from 1930 cm/sec
to 1630 cm/sec after the administration of glime-
piride. The AI was also decreased from 28 % to 18 %
after glimepiride administration. TNF-α, interleukin-6
and hs-CRP was decreased, and adiponectin was
increased as the result of the glimepiride treatment.
3) Change of inflammatory cytokines before and after
therapy
Changes of plasma adiponectin levels are shown in
Figure 2. The treatment had no effect on plasma
adiponectin levels in the GB and INS groups, but were
significantly increased in the GP group (p<0.05). As
shown in Figure 3, TNF-α levels did not significantly
change in theGB and INS groups, but were significantly
decreased in the GP group at the end of the study
(p<0.05). Figures 4 and 5 show that IL-6 and hs-CRP,
the same as TNF-α, did not change significantly in
the GB and INS groups. However, IL-6 and hs-CRP
levels were significantly decreased in the GP group
(p<0.05).
Table 2. Patient profiles after 28 weeks
Group GB GP INS
SBP(mmHg)
BMI(kg/m２)
FPG(mg/dl)
HbA1c(%)
HOMA-IR
148±24
23.2±2.4
142±32
7.6±2.0
2.23±2.2
142±18
22.0±3.6
123±20＊
7.1±1.9＊
1.88±1.1＊＊＊
１50±26
22.4±6.2
146±32
8.3±2.2＊＊
―
＊ P<0.01 vs GB and INS group
＊＊ P<0.01 vs GB and GP group
＊＊＊ P<0.01 vs GB group
Fig. 1. Representative case of baPWV, AI, adiponectin, TNF-α,
IL-6 and hs-CRP before and 28 weeks after glimepiride admini-
stration (73 year old male).
Rt;right, Lt;Left, sys;systolic, dia;diastolic, BP;blood pressure, ABI;
Ankle Brachial Index, baPWV;brachial-ankle pulse wave velocity,
AI ; Augmentation Index, TNF-α ; tumor necrosis factor-α, IL-6 ;
interleukin-6, hs-CRP ; high sensitive-CRP
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4) Changes of atherosclerotic parameters (baPWV/
ABI, augmentation index and HOMA-IR)
Changes in atherosclerotic parameters for each
group are shown in Figure 6. The baPWV did not
change significantly in the GB and INS groups during
the study period, but baPWV significantly decreased
in the GPgroup at the end of the study (p<0.05). Changes
in AI are shown in Figure 7. Similar to baPWV, AI levels
did not significantly change during the study period
in the GB and INS groups, but were significantly
decreased in GP group (p<0.05). HOMA-IR significantly
decreased in the GP groups at the end of the study
(p<0.05), but did not significantly change during the
study period in the GB group.
DISCUSSION
The present study confirms that, in comparing
the GB group and INS groups, HOMA-IR was sig-
nificantly lower in the GP group, suggesting that
glimepiride has a stronger effect on improving insulin
resistance. Furthermore, adiponectin levels were
significantly increased, and both inflammatory cy-
tokines and atherosclerotic parameters (baPWV, AI)
decreased in theGP group. These results suggest that
the administration of glimepiride would have a su-
pressive effect on atherosclerosis.
Conventional SU agents stimulate insulin secretion
from pancreatic β-cells, but they cannot reproduce
the spike-shaped insulin secretion in response to a
meal. As a result, delayed hyperinsulinemia promotes
the accumulation of visceral fat. This suggests that
conventional SU agents worsen insulin resistance and
induce atherosclerosis (7).
Although glimepiride has a hypoglycemic effect
equivalent to the conventional SU agents, its effect
on insulin secretion is weak. Therefore, the findings
here in present study suggest that glimepiride
contributes to the improvement of hyperinsulinemia,
visceral fat accumulation and atherosclerotic sup-
pression.
Fig.2. Changes in plasma adiponectin levels during continuous
therapy (GB and INS groups) or before and 28 weeks after therapy
(GP group).
Fig. 3. Changes in TNF- α levels during continuous therapy (GB
and INS groups) or before and 28 weeks after therapy (GP group).
TNF-α ; tumor necrosis factor -α.
Fig. 4. Changes in IL-6 levels during continuous therapy (GB
and INS groups) or before and 28 weeks after therapy (GP group).
IL-6 ; interleukin-6.
Fig. 5. Changes in hs-CRP levels during continuous therapy (GB
and INS groups) or before and 28 weeks after therapy (GP group).
hs-CRP ; high sensitive-CRP.
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1) Effects of glimepiride on insulin resistance
In the present study, glimepiride was found to improve
insulin resistance, consistent with results reported
in previous studies. This effect appears to be based
on the promotion of glucose-uptake in the liver and
peripheral tissue, and the suppression of glucose
release in the liver (8). It has been reported that
glimepiride promotes the production of fluctose-2,
6-bisphosphate in the liver, promotes the glycolytic
pathway, inhibits gluconeogenesis and glucose release,
and suppresses ketogenesis in an in-vitro study (9).
Glimepiride also promotes glucose-uptake in skeletal
muscle (10) and adipose tissue (11). Consistent with
previous studies (2), we also found that increased
adiponectin and decreased TNF-α levels. Adiponectin
is an adipose tissue-specific glycoprotein that activates
tyrosine kinase activity without connecting directly
to insulin receptors, promotes the tyrosine phos-
phorylation of insulin receptor substrate-1 (IRS-1)
and insulin receptor substrate-2 (IRS-2), and activates
glycogen syntheses through various intracellular
signals. In addition, Yamauchi et al . repoted that
adiponectin increases phosphorylation and activity of
the 5’-AMP-activated protein kinase, and that it si-
multaneously increases glucose uptake in myocytes
and the liver, thereby directly regulates glucose
metabolism and insulin sensitivity (12).
On the other hand, TNF-α decreases the tyrosine
kinase activity of insulin receptors (13), reduces glucose
transport, and induces insulin resistance (14). Adi-
pocytokines, i. e. adiponectin and TNF-α, inhibit and
compete for each other during the biosynthetic phase
in adipose tissue and in peripheral tissue (15).
The mechanism associated with the increase in
adiponectin after glimepiride administration remains
unclear. There are two biosynthetic pathways for the
production of adiponectin, one is the direct production
of adiponectin through Peroxisome Proliferator-
Activated Receptor -gamma (PPAR-γ), an intranuclear
receptor of adipocytes, and the other is the relative
increase induced by the decrease in TNF-α, which
has an inhibitory effect on the production of adi-
ponectin.
Recently, it has been reported that glimepiride
has a direct action on PPAR-γ (16).ThemaximumPPAR-γ
activity enhancing effect of glimepiride is approxi-
mately 20% that of 1 microM pioglitazone. In contrast,
this PPAR-γ stimulatory effect was not observed under
the same conditions with glibenclamide(17). Thismight
be the cause of the significant increase of adi-
ponectin after glimepiride administration .
Adiponectin was increased and TNF-α and HOMA-IR
were decreased significantly after the administra-
tion of glimepiride in the present study. HOMA-IR
has reported to be positively correlated with an index
of insulin resistance by a glucose clampmethod (18),
and HOMA-IR is an established index of insulin
resistance. The present study reveals that glimepiride
Fig. 6. Changes in the baPWV for each groupduring continuous
therapy (GB and INS groups) or before and 28 weeks after
therapy (GP group).
baPWV ; brachial-ankle pulse wave velocity.
Fig. 7. Changes in AI levels during continuous therapy (GB and
INS groups) or before and 28 weeks after therapy (GP group).
AI ; augmentation index.
Fig. 8. Changes in HOMA-IR during continuous therapy (GB
groups) or before and 28 weeks after therapy (GP group).
HOMA-IR ; homeostasis model assessment-insulin resistance.
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has a strong effect on improving insulin resistance in
comparison with glibenclamide.
2) Effects of glimepiride on body weight and BMI
Mori et al. (19) reported that the expression ofmRNA
of TNF-α in retroperitoneal adipose tissue was sig-
nificantly decreased in a glimepiride-administered
group compared with a glibenclamide-administered
group in an experimental study using rats as models.
Further study will be required to investigate the
reason for why TNF-α decreases and adiponectin
increases after administration of glimepiride.
Some clinical researchers have also reported that
neither weight nor BMI is increased after the ad-
ministration of glimepiride (20, 21). In agreement
with these studies, no significant change in BMI was
found in the present study, and our results were in
agreement with previous reports.
3) Anti-atherosclerotic effect of glimepiride
In the initial phases of atherosclerosis, injured
vascular endothelial cells express intercellular adhesion
molecules, such as vascular cell adhesion molecule-1
(VCAM-1), intracellular adhesion molecule - 1(ICAM-1)
and E-secretin, and monocytes became attached to
the vascular wall. Monocytes invade the vascular
endothelium, secrete cytokines such as TNF-α,
accumulate cholesterol esters and are transformed
into foam cells. Furthermore, TNF-α induces the further
adhesion of monocytes. At the injured endothelium,
adiponectin suppresses the expression of these
intercellular adhesion molecules, the levels of which
increase in a TNF-α-dependent manner (22), sup-
presses the expression and secretion of TNF-α(23),
suppresses the expression of class A scavenger receptors
and inhibits the foaming of macrophages (24). These
mechanisms inhibit both the initiation and the de-
velopment of atherosclerosis.
Glimepiride leads to an improvement in lipid
metabolism (25), improves endothelial function due
to the biosynthesis of nitric monoxide (26), and has
anti-oxidative effects (26) in addition to the anti-
atherosclerotic effects (26, 27) mediated by these
cytokines. The present study revealed that biochemical
parameters (IL-6, hs-CRP) significantly decreased,
and pulse wave velocity parameters (baPWV, AI)
also significantly decreased after the administration
of glimepiride. These results suggest that glimepiride
has an anti-atherosclerotic effect. The AHA/ACC
recommendation in 2003 (28) reported the utility of
hs-CRP measurements for the primary prevention
of cardiovascular diseases. In the present study, a
significant decrease in hs-CRP was found after
glimepiride administration, and this drug contrib-
utes to the prevention of coronary heart disease.
The present study suggests that one of the effects
of glimepiride is to improve insulin resistance, but
that it has less possibility for preventing body weight.
Furthermore, glimepiride also has an inhibitory
effect on the initiation and development of athero-
sclerosis. Inukai et al. (3) reported that patients who
had been treated with only SU, or treated with SU
for a short time (less than 5 years), and who were obese
(BMI ≧ 25) or had a high HOMA-IR(HOMA-IR≧ 3),
showed significantly reduced insulin resistance, such
factors are important for predicting therapeutic
effects when the use of glibenclamide is changed to
glimepiride. In conclusion, the present study revealed
that the use of glimepiride as a drugwould be expected
to improve insulin resistance and atherosclerotic
disorders without a gain in body weight.
STUDY LIMITATION
In the present study, the improvement of an ar-
teriosclerotic index by glimepride could not deny
influence by improvement of glycemic control. In a
future study, this problem could be solvedby excluding
the influence of improvement of an arteriosclerotic
index by blood glucose improvement by crossover
method.
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